Intermediate for Tofacitinib. Tofacitinib (trade name Xeljanz, Jakvinus) is a janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib has been approved by the U.S Food and Drug Administration in November 2012.
Product Name: N-((3R,4R)-1-Benzyl-4-methylpiperidin-3-yl)-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine
CAS Number: 477600-73-0
Molecular Weight:  335.451
Molecular Formula:  C20H25N5
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.